Table 2.
Comparison of Lung Transplant Admissions from Two Temporal Cohorts before and after Data-derived Joinpoint
| Pre-LAS (2000–2005) (n = 6,361) | Post-LAS (2006–2011) (n = 9,922) | P Value | |||
|---|---|---|---|---|---|
| Demographics | |||||
| Recipient age, yr | 50.9 | ±0.7 | 54.4 | ±0.6 | <0.0001 |
| Male | 3,279 | (51.6%) | 5,908 | (59.5%) | <0.0001 |
| Race | 0.0024 | ||||
| White | 5,423 | (85.3%) | 8,091 | (81.5%) | |
| Asian/Pacific Islander | 45 | (0.7%) | 147 | (1.5%) | |
| Black | 447 | (7.0%) | 722 | (7.3%) | |
| Hispanic | 319 | (5.0%) | 686 | (6.9%) | |
| Other | 127 | (2.0%) | 276 | (2.8%) | |
| Payer | <0.0001 | ||||
| Medicare | 1,887 | (29.7%) | 3,944 | (39.8%) | |
| Medicaid | 499 | (7.8%) | 572 | (5.8%) | |
| Private/HMO | 3,669 | (57.7%) | 4,838 | (48.8%) | |
| Self-pay/other | 306 | (4.8%) | 568 | (5.7%) | |
| Major medical comorbidities | |||||
| Hypertension | 1,324 | (20.8%) | 3,174 | (32.0%) | <0.0001 |
| Diabetes | 746 | (11.7%) | 2,854 | (28.8%) | <0.0001 |
| Clinical characteristics | |||||
| Medical status prior to transplant | |||||
| Not hospitalized | 5,797 | (91.1%) | 8,157 | (82.2%) | |
| Hospitalized | 564 | (8.9%) | 1,765 | (17.8%) | <0.0001 |
| On ECMO | 39 | (0.6%) | 103 | (1.0%) | 0.25 |
| LAS primary diagnosis group | <0.0001 | ||||
| A (obstructive lung disease) | 2,874 | (45.2%) | 3,051 | (30.8%) | |
| B (pulmonary vascular disease) | 277 | (4.3%) | 281 | (2.8%) | |
| C (CF/immunodeficiency) | 933 | (14.7%) | 1,227 | (12.4%) | |
| D (restrictive lung disease) | 1,995 | (31.4%) | 4,811 | (48.5%) | |
| Other | 282 | (4.4%) | 552 | (5.6%) | |
Definition of abbreviations: CF = cystic fibrosis; ECMO = extracorporeal membrane oxygenation; LAS = lung allocation score; HMO = health maintenance organization.